Growth Metrics

Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2025)

Cellebrite DI's Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $938.9 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 35.95% to $938.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 billion through Dec 2025, up 35.96% year-over-year, with the annual reading at $938.9 million for FY2025, 35.95% up from the prior year.
  • Liabilities and Shareholders Equity came in at $938.9 million for Q4 2025, up from $834.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $938.9 million in Q4 2025 to a low of $315.1 million in Q3 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $503.0 million (2023), against an average of $532.5 million.
  • Year-over-year, Liabilities and Shareholders Equity fell 6.75% in 2021 and then surged 41.47% in 2025.
  • Cellebrite DI's Liabilities and Shareholders Equity stood at $339.8 million in 2021, then increased by 18.69% to $403.3 million in 2022, then surged by 32.13% to $532.9 million in 2023, then increased by 29.59% to $690.6 million in 2024, then soared by 35.95% to $938.9 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Liabilities and Shareholders Equity are $938.9 million (Q4 2025), $834.3 million (Q3 2025), and $787.4 million (Q2 2025).